The week in health tech, explained in plain English.Get the free newsletter →
October 24, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

UPMC Cuts 200 Jobs, Eliminates 300 Vacant Roles

Pittsburgh-based UPMC is laying off approximately 200 employees and eliminating about 300 vacant positions, a health system spokesperson confirmed to Becker's Hospital Review on June 9.

The reductions are aimed primarily at staff who are not in clinical or member-facing roles. "As we regularly reassess our services to ensure they match the needs of our patients and members, limited reductions are occurring," the spokesperson said. UPMC is one of the largest integrated health and insurance systems in the country, operating dozens of hospitals alongside its insurance arm, which gives it more administrative functions to streamline than a standalone hospital.

The cuts fit a broader pattern. Health systems nationwide are working to control labor costs, the largest line item on most hospital budgets, as they navigate thin margins, higher expenses, and reimbursement that has not kept pace. Trimming back-office and vacant roles is a common first lever, allowing systems to reduce spending while preserving bedside staffing levels.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.